03/28/2026
As a medical school professor, I've watched GLP-1 drugs transform diabetes and obesity treatment. Now a Nature Cancer review reveals they may suppress cancer too.
GLP-1 drugs reduce insulin resistance, lower inflammation, and cut body weight -- three of the biggest drivers of tumor growth. But the evidence goes further.
Preclinical studies show GLP-1 receptor signaling directly inhibits tumorigenesis through weight loss-independent mechanisms.
Trial data from people with Type 2 diabetes already shows lower cancer incidence. And modelling suggests 70,000+ cancers could be prevented over 25 years with population-scale GLP-1 use.
This connects directly to metabolic dysfunction as the root cause. Insulin resistance doesn't just cause diabetes -- it feeds cancer cells. Fix the metabolism, starve the tumor.
As I wrote in Lies I Taught in Medical School, we've been compartmentalizing diseases that share the same metabolic origin.
Full breakdown coming on the Health Longevity Secrets podcast.
Source: https://pubmed.ncbi.nlm.nih.gov/41545715/